Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Dexmedetomidine administration routes in FESS
IRCT20190206042646N2Phase 3Not yet recruiting
- Sponsor
- Tehran University of Medical Sciences
- Start
- Dec 2026
- Modality
- Small Molecules, Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial of dexmedetomidine, lidocaine and epinephrine in chronic rhinosinusitis with nasal polyps (CRSwNP) (4 arms), sponsored by Tehran University of Medical Sciences. Primary endpoints: Surgical field quality, Intraoperative vital signs and 3 more. Planned start Dec 2026; status: not yet recruiting.
02
Drugs
dexmedetomidinelidocaineepinephrine
03
Conditions
chronic rhinosinusitis with nasal polyps (CRSwNP)
Beyond the preview
Go deeper on IRCT20190206042646N2.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on IRCT20190206042646N2.